MAPS in the Media

Treating PTSD With MDMA? You Might Have Some Questions.
by Dave Philipps on May 2, 2018. The New York Times reports on the newly published results of MAPS’ U.S. Food and Drug Administration (FDA)-regulated clinical trial of MDMA-assisted psychotherapy for the treatment of posttraumatic stress disorder (PTSD) in veterans, firefighters, and police officers. The New York Times speaks with MAPS-sponsored MDMA researcher Michael Mithoefer, M.D., and trial participants Nigel McCourry and Nicholas Blackston. “I was finally able to process all the dark stuff that happened,” Nicholas Blackston, 32, a study participant who had been a Marine machine-gunner in Iraq, said in an interview. “I was able to forgive myself. It was like a clean sweep.”

Gutfeld on Using Ecstasy to Cure PTSD
by Greg Gutfeld on May 2, 2018. The Five on Fox News examines the history of MAPS, the current PTSD epidemic in veterans, and how MDMA combined with psychotherapy is showing promising results in treating PTSD. “I think every option should be on the table. If it’s a therapy dog, if its psychotherapy, hyperbaric chambers, medical marijuana, MDMA, let’s get it all fixed. Something that’s taboo shouldn’t prevent doctors from trying to help,” states Jesse Watters of Fox News.

CNN
Active Ingredient in Ecstasy May Help Veterans with PTSD, Study Finds
by Susan Scutti on May 3, 2018. CNN covers MAPS’ MDMA-assisted psychotherapy research by speaking with MDMA researcher Michael Mithoefer, M.D., about Phase 2 clinical trials results. “Unlike most other drug studies, MDMA is not being used as a daily drug. Taking it only a few times decreases side effects compared to daily dosing,” and “eliminates the possibility of abuse, since it is administered directly by the therapists,” explains Mithoefer.

Stars and Stripes
Support Grows for Ecstasy-Assisted Psychotherapy to Treat PTSD
by Nikki Wentling on May 2, 2018. Stars and Stripes covers MAPS’ MDMA-assisted psychotherapy research results. MDMA researcher Michael Mithoefer, M.D., says, “results are further evidence that MDMA, used just two times at monthly intervals, can make psychotherapy much more effective and better tolerated.”

Class A Ecstasy Drug Can Help PTSD, Says Study
Published on May 2, 2018. “If you were to design a drug to treat PTSD—MDMA would be it,” says MAPS Founder Rick Doblin, Ph.D., in a new interview with Forces Network. Doblin discusses recently published results from MAPS’ MDMA-assisted psychotherapy for PTSD Phase 2 clinical trials. “What made it so effective for therapy, is that it reduces activity in the amygdala—which is the fear-processing part of the brain, so when trauma is recalled the fear elements are muted so people can look at the trauma and process it,” explains Doblin.

Ecstasy Therapy May Help Service Veterans Suffering PTSD
by Kate Kelland on May 1, 2018. Reuters speaks to MAPS Public Benefit Corporation Clinical Data Scientist Alli Feduccia, Ph.D., about MAPS’ MDMA-assisted psychotherapy for PTSD clinical trials, receiving designation for Breakthrough Therapy, and recently published results in the Lancet Psychiatry.
Ecstasy Ingredient Could Help Ease PTSD Symptoms, Study Finds
by Nicola Davis on May 1, 2018. The Guardian reports that MAPS’ recently published research suggests that MDMA could help reduce symptoms among those living with post-traumatic stress disorder. “It is thought that the MDMA is catalysing the therapy, [rather than] just being effective on its own,” said Dr Al-lison Feduccia, co-author of the research by the MAPS Public Benefit Corporation, a US-based charity focused on research into MDMA and psychotherapy, which funded the study.

Ecstasy May Help Some With PTSD, but Risks Remain
by Steven Reinberg on May 1, 2018. WebMD reports that people suffering from post-traumatic stress disorder might find some relief by using the popular party drug ecstasy, according to MAPS’ recently published research. “Technically, this synthetic drug is called 3,4-methylenedioxy-methamphetamine (MDMA) and it alters mood and perception. When tried with 26 veterans and first responders with PTSD, it helped many of them, investigators found.”

MDMA-Assisted Psychotherapy Improves PTSD Symptoms in Veterans, First Responders
by Matt Hoffman on May 3, 2018. MD Magazine reports an average of 20 US veterans commit suicide each day, and there is a lack of available US Food and Drug Administration (FDA) approved therapies for PTSD outside of a trio of selective serotonin reuptake inhibitors. “In a controlled setting, the use of MDMA adjunct to psychotherapy for patients with PTSD was found to be both effective and well-tolerated, with symptoms of the disorder reduced significantly after 12 months.

Can MDMA Treat Alcoholism? Scientists Begin First Clinical Trials
by Dana Dovey on April 26, 2018. Newsweek features the world’s first clinical trials researching MDMA as an adjunct to psychotherapy as a potential treatment for alcoholism. MDMA researcher Ben Sessa, M.D., and researchers from Imperial College London are leading the clinical trials in the UK. “[MDMA] is able to break down many of the fear barriers that individuals may experience during therapy,” reports Newsweek.

MDMA, Psychotherapy, and the Future of PTSD Treatment
by Tedx Talks on April 5, 2018. Brad Burge of MAPS presents on what it means to live with PTSD, provides a brief history of MDMA, and shares how MDMA-assisted psychotherapy is showing promising results for treating PTSD in a TEDx Talk for TEDx Salem. “Today I’m going to tell you about a new approach being developed to helping people overcome deeply engrained trauma, and it involves only 3 administrations of a drug that’s been around for over 100 years,” begins Burge.

Arizona Researcher Hopes Changes at VA Could Help Study Recruitment Efforts
by Lindsey Reiser on April 5, 2018. Marijuana researcher Sue Sisley, M.D., speaks with AZ Family 3TV CBS 5 about recent U.S. Department of Veterans Affairs bureaucratic changes that may help MAPS’ ongoing clinical trial of smoked marijuana for treating symptoms of PTSD in U.S. veterans, and in turn help more veterans, by allowing VA referrals to the study. “After seven years of struggle with the government, stonewalling at every turn, this week we enrolled our 51st veteran in the study,” explains Sisley. “Let’s make sure science is not being handcuffed by politics.

Bitcoin Mega-Philanthropist ‘Pineapple’ Talks About Psychedelic Research
by Gregory Ferenstein on February 28, 2018. Forbes interviews Bitcoin philanthropist and Pineapple Fund Founder about their dedication to help fund MAPS’ ongoing MDMA research and personal experience receiving ketamine to treat Borderline Personality Disorder. “When I saw MAPS’ work on MDMA-assisted psychotherapy after creating the fund, I was immediately convinced. I’ve personally experienced an incredible benefit and know it works. While ketamine is not MDMA, ketamine has allowed me to explore the depths of my emotions in a way that’s impossible otherwise,” explains Pine.

Bitcoin Could Bankroll MDMA Into the Mainstream as a Therapy Drug
by Sarah Sloat on January 14, 2018. Inverse speaks with the anonymous cryptocurrency philanthropist and Pineapple Fund Founder about their recent pledge to match all new donations to MAPS for Phase 3 trials of MDMA-assisted psychotherapy for PTSD in US dollars or cryptocurrency, up to $4 million in Bitcoin.